Design, synthesis and molecular docking of new N-4-piperazinyl ciprofloxacin-triazole hybrids with potential antimicrobial activity.
Antibacterial
Antifungal
Antimycobacterial
Ciprofloxacin
DNA cleavage assay
Molecular docking
Journal
Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
19
08
2018
revised:
20
04
2019
accepted:
24
04
2019
pubmed:
1
5
2019
medline:
23
9
2020
entrez:
1
5
2019
Statut:
ppublish
Résumé
New N-4-piperazinyl ciprofloxacin-triazole hybrids 6a-o were prepared and characterized. The in vitro antimycobacterial activity revealed that compound 6a experienced promising antimycobacterial activity against Mycobactrium smegmatis compared with the reference isoniazide (INH). Additionally, compound 6a exhibited broad spectrum antibacterial activity against all the tested strains either Gram-positive or Gram-negative bacteria compared with the reference ciprofloxacin. Also, compounds 6g and 6i displayed considerable antifungal activity compared with the reference ketoconazole. DNA cleavage assay of the highly active compounds 6c and 6h showed a good correlation between the Mycobactrium cleaved DNA gyrase assay and their in vitro antimycobactrial activity. Moreover, molecular modeling studies were done for the designed ciprofloxacin derivatives to predict their binding modes towards Topoisomerase II enzyme (PDB: 5bs8).
Identifiants
pubmed: 31039471
pii: S0045-2068(18)30898-8
doi: 10.1016/j.bioorg.2019.102952
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Triazoles
0
Ciprofloxacin
5E8K9I0O4U
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
102952Subventions
Organisme : NCI NIH HHS
ID : R01 CA077373
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.